Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Written by Pamela Kock for The Motley Fool -> Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source. Should you
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli.
Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.
Should you bet on a commercial-stage drugmaker or a pre-clinical genetic pioneer for your 2026 portfolio?
Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME) represent two distinct paths within the high-risk, high-reward world of medical innovation. Choosing between them requires balancing established commercial revenue against moonshot therapeutic potential.
Ocular Therapeutix specializes in bioresorbable hydrogel technology to deliver medicine directly to the eye. Meanwhile, Prime Medicine focuses on its proprietary Prime Editing technology, which functions like a DNA word processor. Both companies target massive unmet needs in human health, but operate at very different stages of corporate maturity.
As one of the many biotech stocks investors are watching, Ocular Therapeutix focuses on treating retinal diseases. Its lead commercial product, Dextenza, is an insert for treating inflammation and pain after ophthalmic surgery. The company relies on three specialty distributors for roughly 75% of its 2025 revenue, which adds a layer of risk to the business.
In FY 2025, the company generated approximately $51.8 million in revenue, which was a decrease of nearly 18.7% from the previous year. This revenue decline was accompanied by a net loss of close to $265.9 million for the period. The net margin for the fiscal year was approximately -513.2%, which helps investors understand the ratio of net losses relative to total sales.
According to the December 2025 balance sheet, the current ratio was nearly 15.4x, which indicates the company has significant liquid assets to cover short-term debts. The debt-to-equity ratio was roughly 0.1x, indicating very low total debt relative to shareholder equity. Free cash flow for the year was negative $216.9 million, representing cash from operations minus capital expenditures.
